首页> 外文期刊>Experimental Brain Research >Locomotor response to levodopa in fluctuating Parkinson’s disease
【24h】

Locomotor response to levodopa in fluctuating Parkinson’s disease

机译:左旋多巴在帕金森病波动中的运动反应

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to quantify the dynamic response of locomotion to the first oral levodopa administration of the day in patients with fluctuating Parkinson’s disease (PD). Stride length, walking speed, cadence and gait variability were measured with an ambulatory gait monitor in 13 PD patients (8 males) with a clinical history of motor fluctuations. The Unified Parkinson’s Disease Rating Scale (UPDRS) gait score (part 29) was also determined by a movement disorders specialist from video recordings. Subjects arrived in the morning in an ‘off’ state (no PD medication) and walked for a maximum length of 100 m. They then took their usual morning dose of oral levodopa and repeated the walking task at 13 min intervals (on average) over a 90 min period. Changes in stride length over time were fit with a Hill (Emax) function. Latency (time until stride length increased 15% of the difference between baseline and maximum response) and the Hill coefficient (shape of the ‘off–on’ transition) were determined from the fitted curve. Latency varied from 4.7 to 53.3 min post-administration [23.31 min (SD 14.9)], and was inversely correlated with age at onset of PD (R = −0.83; P = 0.0004). The Hill coefficient (H) ranged from a smooth hyperbolic curve (0.9) to an abrupt ‘off–on’ transition (16.9), with a mean of 8.1 (SD 4.9). H correlated with disease duration (R = 0.67; P = 0.01) and latency (R = 0.67; P = 0.01), and increased with Hoehn & Yahr stage in the ‘off’ state (P = 0.02) from 5.7 (SD 3.5) (H&Y III) to 11.9 (SD 4.7) (H&Y IV). Walking speed correlated with changes in mean stride length, whereas cadence and gait variability did not. UPDRS gait score also reflected improving gait in the majority of subjects (8), providing clinical confirmation of the objective measures of the locomotor response to levodopa. Increasing abruptness (H) of the ‘off–on’ transition with disease duration is consistent with results from finger-tapping studies, and may reflect reduced buffering capacity of pre-synaptic nigrostriatal dopaminergic neurons. Ambulatory monitoring of gait objectively measures the dynamic locomotor response to levodopa, and this information could be used to improve daily management of motor fluctuations.
机译:这项研究的目的是量化帕金森氏病(PD)波动患者当天运动对第一次口服左旋多巴的动态反应。使用动态步态监测仪对13例具有运动波动临床病史的PD患者(8例男性)进行步幅,步行速度,步频和步态变异性的测量。运动障碍专家还通过录像确定了统一的帕金森氏疾病评分量表(UPDRS)步态得分(第29部分)。受试者以“关闭”状态(无PD药物)在早上到达,并行走了最大100 m的长度。然后,他们按常规早上口服左旋多巴的剂量,并在90分钟内以平均13分钟的间隔重复步行任务。步幅长度随时间的变化符合希尔(Emax)函数。延迟时间(直到步幅增加基线和最大响应之差的15%为止的时间)和希尔系数(“ on-on”过渡的形状)由拟合曲线确定。给药后的潜伏期从4.7分钟到53.3分钟不等[23.31分钟(SD 14.9)],与PD发作时的年龄成反比(R = -0.83; P = 0.0004)。希尔系数(H)范围从平滑的双曲线(0.9)到突然的“开-关”过渡(16.9),平均值为8.1(SD 4.9)。 H与疾病持续时间(R = 0.67; P = 0.01)和潜伏期(R = 0.67; P = 0.01)相关,并且随着Hoehn&Yahr阶段从``关闭''状态(P = 0.02)从5.7(SD 3.5)增加(H&Y III)至11.9(SD 4.7)(H&Y IV)。步行速度与平均步幅的变化相关,而步频和步态的变化则不相关。 UPDRS步态得分也反映了大多数受试者的步态改善(8),为对左旋多巴的运动反应的客观测量提供了临床证实。随着病程的延长,“断断续续”过渡的突然性(H)与手指敲击研究的结果一致,并且可能反映出突触前黑纹状体多巴胺能神经元的缓冲能力降低。对步态的动态监测客观地测量了对左旋多巴的动态运动反应,该信息可用于改善运动波动的日常管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号